Perflubron
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Perflubron
- DrugBank Accession Number
- DB05791
- Background
Perflubron (Oxygent) is being developed as an intravascular oxygen carrier designed to augment oxygen delivery in surgical patients.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 498.962
Monoisotopic: 497.891192132 - Chemical Formula
- C8BrF17
- Synonyms
- Perflubron
- Perfluorooctyl-bromide
Pharmacology
- Indication
Investigated for use/treatment in cardiac surgery, hemorrhage, and ileus.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Perflubron emulsion (Oxygent) maintains hemodynamic stability during major surgery, thereby potentially reducing or avoiding intraoperative transfusions of donor blood in major surgery.Perflubron emulsion has ability to enable patients to be physiologically stable and safe at lower intraoperative Hb levels.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- Oxygent
Categories
- ATC Codes
- V08CX01 — Perflubron
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as organofluorides. These are compounds containing a chemical bond between a carbon atom and a fluorine atom.
- Kingdom
- Organic compounds
- Super Class
- Organohalogen compounds
- Class
- Organofluorides
- Sub Class
- Not Available
- Direct Parent
- Organofluorides
- Alternative Parents
- Organobromides / Hydrocarbon derivatives / Alkyl fluorides / Alkyl bromides
- Substituents
- Aliphatic acyclic compound / Alkyl bromide / Alkyl fluoride / Alkyl halide / Hydrocarbon derivative / Organobromide / Organofluoride
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- fluoroalkane (CHEBI:38803)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Q1D0Q7R4D9
- CAS number
- 423-55-2
- InChI Key
- WTWWXOGTJWMJHI-UHFFFAOYSA-N
- InChI
- InChI=1S/C8BrF17/c9-7(22,23)5(18,19)3(14,15)1(10,11)2(12,13)4(16,17)6(20,21)8(24,25)26
- IUPAC Name
- 1-bromo-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane
- SMILES
- FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br
References
- General References
- Gale SC, Gorman GD, Copeland JG, McDonagh PF: Perflubron emulsion prevents PMN activation and improves myocardial functional recovery after cold ischemia and reperfusion. J Surg Res. 2007 Mar;138(1):135-40. Epub 2006 Dec 14. [Article]
- Rosen NA, Hopf HW, Hunt TK: Perflubron emulsion increases subcutaneous tissue oxygen tension in rats. Wound Repair Regen. 2006 Jan-Feb;14(1):55-60. [Article]
- External Links
- PubChem Compound
- 9873
- PubChem Substance
- 175427032
- ChemSpider
- 9489
- ChEBI
- 38803
- ChEMBL
- CHEMBL1200866
- ZINC
- ZINC000008214650
- Wikipedia
- Oxygent
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data1 Completed Not Available Asthma 1 somestatus stop reason just information to hide 1 Completed Treatment Chronic Lung Disease of Prematurity 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0314 mg/mL ALOGPS logP 4.74 ALOGPS logP 6.64 Chemaxon logS -4.2 ALOGPS Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 0 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 0 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 48.52 m3·mol-1 Chemaxon Polarizability 21.18 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9968 Blood Brain Barrier + 0.9896 Caco-2 permeable + 0.6277 P-glycoprotein substrate Non-substrate 0.8924 P-glycoprotein inhibitor I Non-inhibitor 0.9533 P-glycoprotein inhibitor II Non-inhibitor 0.9264 Renal organic cation transporter Non-inhibitor 0.9207 CYP450 2C9 substrate Non-substrate 0.8648 CYP450 2D6 substrate Substrate 0.7099 CYP450 3A4 substrate Non-substrate 0.7486 CYP450 1A2 substrate Non-inhibitor 0.6432 CYP450 2C9 inhibitor Non-inhibitor 0.7876 CYP450 2D6 inhibitor Non-inhibitor 0.9515 CYP450 2C19 inhibitor Non-inhibitor 0.7867 CYP450 3A4 inhibitor Non-inhibitor 0.9553 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8993 Ames test Non AMES toxic 0.8692 Carcinogenicity Carcinogens 0.6509 Biodegradation Not ready biodegradable 0.9682 Rat acute toxicity 1.6745 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9796 hERG inhibition (predictor II) Non-inhibitor 0.9093
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 174.38576 predictedDeepCCS 1.0 (2019) [M+H]+ 176.78133 predictedDeepCCS 1.0 (2019) [M+Na]+ 183.29051 predictedDeepCCS 1.0 (2019)
Drug created at November 18, 2007 18:27 / Updated at October 30, 2024 22:48